Selenium supplementation in radiotherapy patients: do we need to measure selenium levels in serum or blood regularly prior radiotherapy?

详细信息    查看全文

• 作者：Ralph Muecke (1) (2)
  Oliver Micke (3)
  Lutz Schomburg (4)
  Klaus Kisters (5)
  Jens Buentzel (6)
  Jutta Huebner (7)
  Jan Kriz (8)
  
  1. Department of Radiotherapy ; Lippe Hospital Lemgo ; Rintelner Str. 85 ; D-32657 ; Lemgo ; Germany
  2. Department of Radiotherapy and Radiation Oncology ; Ruhr University Bochum ; Bochum ; Germany
  3. Department of Radiotherapy and Radiation Oncology ; Franziskus Hospital ; Bielefeld ; Germany
  4. Institute for Experimental Endocrinology ; Charit茅 Berlin ; Germany
  5. Department of Internal Medicine ; St. Anna Hospital ; Herne ; Germany
  6. Department of Otolaryngology ; S眉dharz Hospital ; Nordhausen ; Germany
  7. Working Group Integrative Oncology ; German Cancer Society ; Berlin ; Germany
  8. Department of Radiotherapy and Radiation Oncology ; M眉nster University Hospital ; M眉nster ; Germany
  
• 关键词：Selenium ; Supplementation ; Clinical studies ; Selenoproteins ; Radiotherapy
• 刊名：Radiation Oncology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：9
• 期：1
• 全文大小：130 KB
• 参考文献：1. Puspitasari, IM, Abdulah, R, Yamazaki, C, Kameo, S, Nakano, T, Koyama, H (2014) Updates on clinical studies of selenium supplementation in radiotherapy. Radiat Oncol 9: pp. 125 CrossRef
  2. Meyer, HA, Endermann, T, Stephan, C, Stoedter, M, Behrends, T, Wolff, I, Jung, K, Schomburg, L (2012) Selenoprotein P Status Correlates to Cancer-Specific Mortality in Renal Cancer Patients. PLoS One 7: pp. e46644 CrossRef
  3. Xia, Y, Hill, KE, Byrne, DW, Xu, J, Burk, RF (2005) Effectiveness of selenium Supplements in a low-selenium area of China. Am J Clin Nutr 81: pp. 829-834
  4. Burk, RF, Norsworthy, BK, Hill, KE, Motley, AK, Byrne, DW (2006) Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol Biomarkers Prev 15: pp. 804-810 CrossRef
  5. Persson-Moschos, M, Alfthan, G, Akesson, B (1998) Plasma selenoprotein P levels of healthy males in different selenium status after oral supplementation with different forms of selenium. Eur J Clin Nutr 52: pp. 363-367 CrossRef
  6. Hurst, R, Armah, CN, Dainty, JR, Hart, DJ, Teucher, B, Goldson, AJ, Broadley, MR, Motley, AK, Fairweather-Tait, SJ (2010) Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 91: pp. 923-931 CrossRef
  7. Muecke, R, Schomburg, L, Buentzel, J, Kisters, K, Micke, O (2010) Blood selenium Status in tumor patients: Omnia sunt venena, nihil est sine veneno. Sola dosis facit venenum. Trace Elem Electrolytes 27: pp. 181-182
  8. Muecke, R, Schomburg, L, Buentzel, J, Kisters, K, Micke, O (2010) Selenium or no selenium-that is the question in tumor patients: a new controversy. Integr Cancer Ther 9: pp. 136-141 CrossRef
  9. Bleys, J, Navas-Acien, A, Guallar, E (2008) Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 168: pp. 404-410 CrossRef
  10. Karp, DD, Lee, SJ, Keller, SM, Wright, GS, Aisner, S, Belinsky, SA, Johnson, DH, Johnston, MR, Goodman, G, Clamon, G, Okawara, G, Marks, R, Frechette, E, McCaskill-Stevens, W, Lippman, SM, Ruckdeschel, J, Khuri, FR (2013) Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non-Small- Cell LungCancer: ECOG 5597. J Clin Oncol 31: pp. 4179-4187 CrossRef
  11. Lippman, SM, Klein, EA, Goodman, PJ, Lucia, MS, Thompson, IM, Ford, LG, Parnes, HL, Minasian, LM, Gaziano, JM, Hartline, JA, Parsons, JK, Bearden, JD, Crawford, ED, Goodman, GE, Claudio, J, Winquist, E, Cook, ED, Karp, DD, Walther, P, Lieber, MM, Kristal, AR, Darke, AK, Arnold, KB, Ganz, PA, Santella, RM, Albanes, D, Taylor, PR, Probstfield, JL, Jagpal, TJ, Crowley, JJ (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 301: pp. 39-51 CrossRef
  12. Muecke, R, Schomburg, L, Glatzel, M, Bernd-Skorka, R, Baaske, D, Reichl, B, Buentzel, J, Kundt, G, Prott, FJ, Vries, A, Stoll, G, Kisters, K, Bruns, F, Schaefer, U, Willich, N, Micke, O (2010) Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 70: pp. 828-835 CrossRef
  
• 刊物主题：Oncology; Radiotherapy;
• 出版者：BioMed Central
• ISSN：1748-717X

文摘

Considering the review by Puspitasari and colleagues, an additional discussion of the endpoints of the Se supplementation studies described would be helpful. In our view, selenium can safely be given to selenium-deficient cancer patients prior to and during radiotherapy. Therefore, in order to help the radiation oncologist in decision making, we strongly advocate to determine the selenium status prior to and during a potential adjuvant selenium supplementation, e.g. when trying to ease the side-effects of radiation treatment or in the aftercare situation when the selenium status may become insufficient.